The University of California, Irvine is commencing recruitment for the clinical trial of the Treatment of Meniere's Disease With Migraine Medications.
The trial officially began on the August 1, 2022 and is planned to complete by August 2024.
Meniere's disease (MD) is a chronic disease with a variety of fluctuating signs and symptoms, which include vertigo, hearing loss, tinnitus (ringing noise in the ear), aural pressure (feeling of ear fullness), and disequilibrium (lack of stability).
The following patients may be included into this study: those with active or frequent Meniere's Disease; Male or female between the ages of 25 to 85 years; participants must be able to read and write in the English language to provide consenting.
Whereas patients with history of surgery for Meniere's Disease are exluded. There is a number of other exclusion criteria that may be consulted here: profile: https://ichgcp.net/clinical-trials-registry/NCT05582837.